舒利迭对COPD合并呼吸衰竭患者的脑钠肽和超敏C反应蛋白的影响

Impact of Seretide for COPD Patients with Respiratory Failure on Brain Natriuretic Peptide and High Sensitivity C-reactive Protein

目的：观察舒利迭对COPD合并呼吸衰竭患者的的疗效及其对脑钠肽（BNP）和超敏C反应蛋白（hs-CRP）的影响。方法：选取2010年1月~2011年12月我院收治的COPD合并急性呼吸衰竭患者86例,随机分为观察组和对照组,每组各43例。对照组予以无创呼吸机辅助呼吸等支持对症治疗,观察组在对照组的基础上予以舒利迭治疗。观察两组的疗效,动脉血二氧化碳分压（PaCO2）,动脉血氧分压（PaO2）,PH值,BNP和hs-CRP的变化。结果：观察组的总有效率为93.02%,而对照组的疗效为72.09%,差异有统计学意义（P〈0.05）。与治疗前比较两组治疗后的PaO2和PH明显提高,观察组的提高水平较对照组更为明显（P〈0.01）,而两组的PaCO2、BNP和hs-CRP水平均较治疗前明显降低,而观察组的降低水平更为明显（P〈0.01）。结论：舒利迭对COPD合并呼吸衰竭的疗效显著,其机理可能与降低BNP和hs-CRP水平有关。

Objective： To investigate the effect of seretide on COPD patients with respiratory failure and its impact on brain natriuretic peptide（BNP） and high-sensitivity C-reactive protein（hs-CRP）.Methods： Randomly divide 86 COPD patients with acute respiratory failure treated in our hospital from January 2009 to December 2011 into observation group and control group,43 cases in each group.The patients in control group were given non-invasive ventilator-assisted breathing and support to symptomatic treatment and so on,and the patients in observation group were given seretide on the basis of the control group.Observe the therapeutic effect of each group and the rangeability of partial pressure carbon dioxide（PaCO2）,oxygen saturation（PaO2）,PH,BNP and of hs-CRP in each group.Results： The total effective rate was 93.02% in observation group and 72.09% in control group,the difference was statistically significant（P0.05）.After treatment,the levels of PaO2 and PH significantly improved in both groups compared with that before treatment,the levels rise more obviously in observation group than those in control group（P 0.01）;The levels of PaCO2,BNP and hs-CRP decreased significantly than those before treatment,while the levels of the observation group was lower more obviously（P0.01）.Conclusion： The efficacy of seretide for COPD patients with respiratory failure is obvious,and its mechanism may be associated with the levels of BNP and hs-CRP.